Last R$16.72 BRL
Change Today +0.11 / 0.66%
Volume 290.2K
As of 11:19 AM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

hypermarcas sa (HYPE3) Snapshot

Open
R$16.50
Previous Close
R$16.61
Day High
R$16.97
Day Low
R$16.50
52 Week High
09/1/14 - R$19.69
52 Week Low
03/5/14 - R$14.22
Market Cap
10.6B
Average Volume 10 Days
2.6M
EPS TTM
R$0.63
Shares Outstanding
632.1M
EX-Date
05/2/13
P/E TM
26.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for HYPERMARCAS SA (HYPE3)

Related News

No related news articles were found.

hypermarcas sa (HYPE3) Related Businessweek News

No Related Businessweek News Found

hypermarcas sa (HYPE3) Details

Hypermarcas S.A., a consumer goods company, is engaged in the development, production, and sale of drug, health, beauty, and personal care products in Brazil. It operates in two segments, Pharmaceutical and Consumer. The company offers sweeteners under the Adocyl, Finn, and Zero-Cal names; and beauty and personal care products, including bleach and hydrogen peroxide, body deodorants, colognes, coloring, deodorants, hair line, hair styling, nail polish, shaving products, skin care, soap, tanner/sunscreen, and transformation products. It also provides child care and health products, such as absorbents, accessories, antiseptics, baby bottles, baby lines, baby powder, toothbrushes and dental products, cloths, condoms, baby diapers, dental creams and gels, dental floss and tapes, diaper rash cream, disposable pads, disposable underwear, feminine hygiene products, diapers, intimate hygiene products, kids lines, lubricants, moistened towels, oral antiseptics, oral supplements, palinets, wet wipes, and cottons. In addition, the company offers pharmaceutical products, including over-the-counter medications, such as laxative, antacid, antispasmodic, topical antiseptic, topical, nasal decongestant drugs, and other products; prescription medications under the Farmasa, Neo Química, and Luper names; generic medications; and dermocosmetics. Hypermarcas S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

12,569 Employees
Last Reported Date: 02/22/14
Founded in 2001

hypermarcas sa (HYPE3) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hypermarcas sa (HYPE3) Key Developments

Hypermarcas Reports Earnings Results for the Third Quarter and Nine Months of 2014

Hypermarcas reported earnings results for the third quarter and nine months of 2014. For the quarter, the company reported net revenues of BRL 1,187,000,000, a 6.8% growth compared to the same period of last year. Excluding the impact of third-party manufacturing contract with Merck Sharp & Dohme, the net revenue growth was 10.7% compared to the same period of last year. In the third quarter, the company posted adjusted EBITDA of BRL 286 million, an 8.1% growth compared to the same period of last year, with a margin of 24.1% of net revenues, a 30 bps expansion against the same quarter of last year. Free cash flow reached BRL 188.1 million in the third quarter, a 10% growth compared to same period of last year. For the nine months, the company reported net revenues of BRL 3,379,000,000, a 7.6% growth compared to the same period of last year and excluding the Merck Sharp -- MSD contract, a 9.1% growth. In the 9 months of this year, adjusted EBITDA increased 11% to BRL 833 million, with a margin of 24.6%, which is equivalent to 75.7% of company's guidance toward the full year. Free cash flow was BRL 434 million, a 20.2% growth compared to the same period of last year.

Hypermarcas S.A., Q3 2014 Earnings Call, Oct 27, 2014

Hypermarcas S.A., Q3 2014 Earnings Call, Oct 27, 2014

Hypermarcas S.A. Presents at UBS Global Emerging Markets One-on-One Conference, Dec-02-2014

Hypermarcas S.A. Presents at UBS Global Emerging Markets One-on-One Conference, Dec-02-2014 . Venue: The Westin New York Grand Central, 212 East 42nd Street at 3rd Avenue, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HYPE3:BZ R$16.73 BRL +0.12

HYPE3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,385 GBp 0.00
Johnson & Johnson $105.09 USD +0.50
Pfizer Ltd/India 2,038 INR +22.40
Sanofi €74.99 EUR -0.65
View Industry Companies
 

Industry Analysis

HYPE3

Industry Average

Valuation HYPE3 Industry Range
Price/Earnings 24.5x
Price/Sales 2.1x
Price/Book 1.3x
Price/Cash Flow 24.7x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERMARCAS SA, please visit www.hypermarcas.com.br. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.